Anti-PD-1/PD-L1 antibody therapy has changed the treatment landscape and led to a paradigm shift in treatment strategies in NSCLC, and is now a standard-of-care for NSCLC [6,7,8]. Here, PDCD1 is linked to non-small cell lung carcinoma.